Boosted Atazanavir
PreclinicalSmall molecule
Boosted Atazanavir is one of 10 small molecule programs targeting Osteopenia. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Osteopenia
#DrugCompanyPhaseTrials
1Evista
Eli LillyApproved
Epidiolex
Jazz PharmaceuticalsApproved
Estrace
Novo NordiskApproved
Prolia
OOrganon and Co
Approved
Jadelle
IItalian Network for Tumor Biotherapy Foundation
Approved
Forteo
AAlmaject
Approved
Calciferol
Jazz PharmaceuticalsPreclinical
Epivir
GGlaxo Dba Glaxosmithkline
Preclinical
Calcium
Eli LillyPreclinical
Boosted Atazanavir
PPhoenix Children's Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Children1 trial
Atazavanir/Ritonavir-based HAART in Children
Completed·TThe HIV Netherlands Australia Thailand Research Collaboration·Phase 2·NCT01656109·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Boosted Atazanavir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPhoenix Children's Hospital